Cellares secures new funding, partnerships and FDA recognition as it prepares for commercial-scale cell therapy manufacturing ...

Cellares will adapt and automate the SBT-77-7101 manufacturing process from Sonoma for use with Cell Shuttle.

Levered free cash flow was -14.46 million USD reflecting a 38.23% change from the previous quarter. In the most recent fiscal year, Tscan Therapeutics generated -135.32 million USD in cash from ...

Tscan Therapeutics has a price-to-earnings (P/E) ratio of -0.49 (TTM). This compares to an industry average of -14.44. The P/S ratio for Tscan Therapeutics is currently 7.65 (TTM). What is Tscan ...

Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

TScan Therapeutics Inc. Annual stock financials by MarketWatch. View the latest TCRX financial statements, income statements and financial ratios.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.